share_log

SAB Biotherapeutics Analyst Ratings

SAB Biotherapeutics Analyst Ratings

SAB 生物治疗分析师评级
Benzinga ·  2023/10/05 10:27
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/05/2023 Ladenburg Thalmann Downgrades Buy → Neutral
08/21/2023 177.78% HC Wainwright & Co. $4 → $2 Maintains Buy
06/21/2023 455.56% HC Wainwright & Co. → $4 Reiterates Buy → Buy
06/16/2023 455.56% HC Wainwright & Co. → $4 Reiterates Buy → Buy
06/15/2023 316.67% Chardan Capital → $3 Reiterates Buy → Buy
05/17/2023 455.56% HC Wainwright & Co. → $4 Reiterates Buy → Buy
04/27/2023 316.67% Chardan Capital → $3 Reiterates → Buy
04/13/2023 455.56% HC Wainwright & Co. → $4 Reiterates → Buy
04/03/2023 455.56% HC Wainwright & Co. → $4 Reiterates → Buy
11/29/2022 455.56% HC Wainwright & Co. → $4 Initiates Coverage On → Buy
08/11/2022 316.67% Chardan Capital $7 → $3 Maintains Buy
05/13/2022 872.22% Chardan Capital $10 → $7 Maintains Buy
04/01/2022 1288.89% Chardan Capital $17 → $10 Maintains Buy
11/05/2021 2261.11% Chardan Capital → $17 Initiates Coverage On → Buy
11/02/2021 3094.44% Baird → $23 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
10/05/2023 - 拉登堡·塔尔曼 评级下调 购买→中性
2023年08月21日 177.78% HC Wainwright公司 $4→$2 维护
2023年6月21日 455.56% HC Wainwright公司 →$4 重申 购买→购买
06/16/2023 455.56% HC Wainwright公司 →$4 重申 购买→购买
2023/06/15 316.67% 查尔丹资本 →$3 重申 购买→购买
2023年05月17日 455.56% HC Wainwright公司 →$4 重申 购买→购买
04/27/2023 316.67% 查尔丹资本 →$3 重申 →购买
04/13/2023 455.56% HC Wainwright公司 →$4 重申 →购买
04/03/2023 455.56% HC Wainwright公司 →$4 重申 →购买
2022年11月29日 455.56% HC Wainwright公司 →$4 开始承保 →购买
2022年08月11日 316.67% 查尔丹资本 $7→$3 维护
2022年05月13日 872.22% 查尔丹资本 $10→$7 维护
04/01/2022 1288.89% 查尔丹资本 $17→$10 维护
2021年11月05日 2261.11% 查尔丹资本 →$17 开始承保 →购买
11/02/2021 3094.44% 贝尔德 →$23 开始承保 →跑赢大盘

What is the target price for SAB Biotherapeutics (SABS)?

SAB生物疗法(SABS)的目标价格是多少?

The latest price target for SAB Biotherapeutics (NASDAQ: SABS) was reported by Ladenburg Thalmann on October 5, 2023. The analyst firm set a price target for $0.00 expecting SABS to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

拉登堡·塔尔曼于2023年10月5日报道了SAB生物治疗公司(纳斯达克:SABS)的最新目标价。这家分析公司将目标价定为0.00美元,预计SABS将在12个月内下跌(跌幅可能为-100.00%)。去年有10家分析公司公布了评级。

What is the most recent analyst rating for SAB Biotherapeutics (SABS)?

SAB BioTreateutics(SABS)最近的分析师评级是多少?

The latest analyst rating for SAB Biotherapeutics (NASDAQ: SABS) was provided by Ladenburg Thalmann, and SAB Biotherapeutics downgraded their neutral rating.

纳斯达克(Sequoia Capital:SABS)的最新分析师评级由拉登堡·塔尔曼提供,SAB生物治疗公司下调了其中性评级。

When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?

SAB BioTreateutics(SABS)的下一次分析师评级将于何时发布或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.

分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公共财务报表,与SAB BioTreateutics的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。SAB生物疗法的上一次评级是在2023年10月5日提交的,所以你应该预计下一次评级将在2024年10月5日左右的某个时候提供。

Is the Analyst Rating SAB Biotherapeutics (SABS) correct?

分析师对SAB生物疗法(SABS)的评级正确吗?

While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a downgraded with a price target of $0.00 to $0.00. The current price SAB Biotherapeutics (SABS) is trading at is $0.72, which is out of the analyst's predicted range.

虽然评级是主观的,并将发生变化,但最新的SAB BioTreateutics(SABS)评级被下调,目标价为0.00美元至0.00美元。SAB BioTreateutics(SABS)目前的股价为0.72美元,超出了分析师的预测区间。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发